CV Sciences (CVSI) Non-Current Debt (2013 - 2025)

CV Sciences' (CVSI) quarterly Non-Current Debt came in at $387000.0 in Q4 2025, down 23.21% quarter-over-quarter from $504000.0 in Q3 2025.

CV Sciences (CVSI) Non-Current Debt (2013 - 2025) Analysis & Trends

CV Sciences has disclosed Non-Current Debt across 7 years of filings, most recently posting $387000.0 for Q4 2025.

Non-Current Debt for Q4 2025 came in at $387000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $387000.0 (changed N/A YoY), and the FY2025 annual result was $387000.0, changed N/A from the prior year.
Non-Current Debt came in at $387000.0 for Q4 2025 at CV Sciences, down from $504000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $504000.0 in Q3 2025 to a low of $208000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Teva Pharmaceutical Industries	38.34 Bn	34.60 Bn	1.97 Bn	14.02 Bn
2	Zoetis	33.27 Bn	31.33 Bn	1.62 Bn	9.05 Bn
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn	-
4	Aurora Cannabis	17.11 Bn	17.03 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.37 Bn	15.05 Bn	800.70 Mn	-
6	Elanco Animal Health	11.78 Bn	11.35 Bn	785.00 Mn	3.92 Bn
7	Alkermes	7.05 Bn	6.54 Bn	-116.06 Mn	1.48 Bn
8	Lantheus Holdings	6.49 Bn	5.99 Bn	230.92 Mn	569.60 Mn
9	Hims & Hers Health	6.19 Bn	5.44 Bn	396.79 Mn	-
10	CV Sciences	-	-	1.56 Mn	-

Download Data